FILE PHOTO: The brand for Biohaven Pharmaceutical Holding Firm is displayed on a display throughout the firm’s IPO on the ground of the New York Inventory Trade (NYSE) in New York, U.S., Could 4, 2017. REUTERS/Brendan McDermid

(Reuters) – Biohaven Pharmaceutical Holding Firm Ltd mentioned on Tuesday two doses of its experimental therapy for acute migraine have been efficient in decreasing complications in a big examine, sending its shares up 8% earlier than the bell.

The drug, vazegepant, belongs to a brand new class of remedies for migraine referred to as CGRP inhibitors.

Vazegepant is the primary CGRP therapy delivered in an intranasal formulation, which advantages…

Source link

Please follow and like us: